Warning Letters | FDA
FDA issued new warning letters targeting dietary supplement companies for labeling violations, including unauthorized structure/function claims and failure to comply with GMPs. This signals increased enforcement focus on labeling accuracy and NDI notifications.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; FDA may issue warning letters or seize products for non-compliance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA published new warning letters highlighting specific labeling violations (e.g., unsubstantiated claims, missing Supplement Facts, GMP failures). This indicates a stricter enforcement posture.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review all product labels for compliance with FDA labeling requirements, ensure structure/function claims are substantiated and include required disclaimers, verify NDI notifications for new ingredients, and audit GMP documentation.
Deadline
Immediately; FDA may issue warning letters or seize products for non-compliance.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO
- US FDA New Dietary Ingredient Notification Submissions in the Last 4 Years - CIRS Group